JPH10503093A - 無蛋白培養における生物製剤の製造法 - Google Patents
無蛋白培養における生物製剤の製造法Info
- Publication number
- JPH10503093A JPH10503093A JP51572696A JP51572696A JPH10503093A JP H10503093 A JPH10503093 A JP H10503093A JP 51572696 A JP51572696 A JP 51572696A JP 51572696 A JP51572696 A JP 51572696A JP H10503093 A JPH10503093 A JP H10503093A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- cell
- culture
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 129
- 229960000074 biopharmaceutical Drugs 0.000 title description 5
- 241000700605 Viruses Species 0.000 claims abstract description 553
- 238000000034 method Methods 0.000 claims abstract description 206
- 239000002028 Biomass Substances 0.000 claims abstract description 99
- 229960005486 vaccine Drugs 0.000 claims abstract description 83
- 206010022000 influenza Diseases 0.000 claims abstract description 64
- 230000004913 activation Effects 0.000 claims abstract description 62
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 57
- 230000003612 virological effect Effects 0.000 claims abstract description 37
- 230000012010 growth Effects 0.000 claims abstract description 27
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 17
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 17
- 239000013603 viral vector Substances 0.000 claims abstract description 9
- 238000000746 purification Methods 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 397
- 241000712461 unidentified influenza virus Species 0.000 claims description 178
- 101710154606 Hemagglutinin Proteins 0.000 claims description 111
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 111
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 111
- 101710176177 Protein A56 Proteins 0.000 claims description 111
- 239000000185 hemagglutinin Substances 0.000 claims description 109
- 238000004113 cell culture Methods 0.000 claims description 102
- 239000002609 medium Substances 0.000 claims description 90
- 108091005804 Peptidases Proteins 0.000 claims description 89
- 239000004365 Protease Substances 0.000 claims description 85
- 235000013601 eggs Nutrition 0.000 claims description 82
- 239000000427 antigen Substances 0.000 claims description 75
- 108091007433 antigens Proteins 0.000 claims description 75
- 102000036639 antigens Human genes 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 210000003501 vero cell Anatomy 0.000 claims description 66
- 239000000126 substance Substances 0.000 claims description 63
- 238000003776 cleavage reaction Methods 0.000 claims description 62
- 230000007017 scission Effects 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 230000002238 attenuated effect Effects 0.000 claims description 37
- 208000015181 infectious disease Diseases 0.000 claims description 37
- 241000287828 Gallus gallus Species 0.000 claims description 35
- 235000013330 chicken meat Nutrition 0.000 claims description 35
- 230000000890 antigenic effect Effects 0.000 claims description 31
- 241000124008 Mammalia Species 0.000 claims description 22
- 108010056079 Subtilisins Proteins 0.000 claims description 20
- 102000005158 Subtilisins Human genes 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 20
- 108010059712 Pronase Proteins 0.000 claims description 19
- 231100000433 cytotoxic Toxicity 0.000 claims description 18
- 230000001472 cytotoxic effect Effects 0.000 claims description 18
- 231100000331 toxic Toxicity 0.000 claims description 18
- 230000002588 toxic effect Effects 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 16
- 108010006232 Neuraminidase Proteins 0.000 claims description 15
- 102000005348 Neuraminidase Human genes 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- 241000283690 Bos taurus Species 0.000 claims description 11
- 108090001109 Thermolysin Proteins 0.000 claims description 11
- 241000700618 Vaccinia virus Species 0.000 claims description 11
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 10
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 9
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 8
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 8
- 239000002753 trypsin inhibitor Substances 0.000 claims description 8
- 241000711504 Paramyxoviridae Species 0.000 claims description 7
- 108010067390 Viral Proteins Proteins 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 241000726306 Irus Species 0.000 claims description 6
- 241000702247 Reoviridae Species 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 241000709721 Hepatovirus A Species 0.000 claims description 5
- 241000712464 Orthomyxoviridae Species 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 4
- 229960000182 blood factors Drugs 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 4
- 241000712892 Arenaviridae Species 0.000 claims description 3
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 241000712890 Junin mammarenavirus Species 0.000 claims description 3
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 241000709664 Picornaviridae Species 0.000 claims description 3
- 241000700625 Poxviridae Species 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 241000710799 Rubella virus Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241000701242 Adenoviridae Species 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 108700010877 adenoviridae proteins Proteins 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 241000282887 Suidae Species 0.000 claims 2
- 241000710781 Flaviviridae Species 0.000 claims 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 1
- 241000287462 Phalacrocorax carbo Species 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 230000001976 improved effect Effects 0.000 abstract description 5
- 239000012190 activator Substances 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 102000035195 Peptidases Human genes 0.000 description 83
- 238000001994 activation Methods 0.000 description 58
- 235000018102 proteins Nutrition 0.000 description 55
- 108090000631 Trypsin Proteins 0.000 description 42
- 102000004142 Trypsin Human genes 0.000 description 42
- 239000012588 trypsin Substances 0.000 description 41
- 229960001322 trypsin Drugs 0.000 description 41
- 210000002966 serum Anatomy 0.000 description 33
- 239000000047 product Substances 0.000 description 28
- 208000037797 influenza A Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 239000012530 fluid Substances 0.000 description 15
- 210000001161 mammalian embryo Anatomy 0.000 description 14
- 239000000356 contaminant Substances 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 12
- 210000003292 kidney cell Anatomy 0.000 description 12
- 210000002257 embryonic structure Anatomy 0.000 description 11
- 210000004962 mammalian cell Anatomy 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 241000702670 Rotavirus Species 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 210000004748 cultured cell Anatomy 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 229960003971 influenza vaccine Drugs 0.000 description 8
- 239000002356 single layer Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000011031 large-scale manufacturing process Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241001500351 Influenzavirus A Species 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000004264 monolayer culture Methods 0.000 description 6
- 241000277331 Salmonidae Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108010006303 Carboxypeptidases Proteins 0.000 description 4
- 102000005367 Carboxypeptidases Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- -1 Ki Motrypsin Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000208474 Protea Species 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108090000317 Chymotrypsin Proteins 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 241000845082 Panama Species 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 101710118538 Protease Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960002376 chymotrypsin Drugs 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- 101710186708 Agglutinin Proteins 0.000 description 2
- 241000252229 Carassius auratus Species 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 241000700586 Herpesviridae Species 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940124873 Influenza virus vaccine Drugs 0.000 description 2
- 241001500350 Influenzavirus B Species 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 241001137860 Rotavirus A Species 0.000 description 2
- 241001137861 Rotavirus B Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 241001439211 Almeida Species 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100022977 Antithrombin-III Human genes 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710200158 DNA packaging protein Proteins 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710160913 GemA protein Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HCIHJOTZGZSMLV-UHFFFAOYSA-N Lutinine Natural products O=C1C(=Nc2ccccc2)C=C(Nc3ccccc3)c4ccccc14 HCIHJOTZGZSMLV-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100355655 Mus musculus Eras gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241001506005 Rotavirus C Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000003836 bluetongue Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035071 co-translational protein modification Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 231100000175 potential carcinogenicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)無蛋白培地中のみで培養した脊椎動物細胞培養を得、 (b)該培養をウイルスに感染させ、 (c)該ウイルスを感染させた該細胞培養をインキュベーションして該ウイルス を増殖させる工程を含むウイルス抗原の製造方法。 2.該ウイルスが該培養で複数回連続的に継代することなく増殖するものであ る請求項1に記載の方法。 3.該ウイルスがオルソミクソウイルス科、パラミクソウイルス科、レオウイ ルス科、ピコルナウイルス科、フラビウイルス科、アレナウイルス科、ヘルペス ウイルス科、ポックスウイルス科、およびアデノウイルス科からなる群から選ば れるものである請求項2に記載の方法。 4.該ウイルスがポリオウイルス、HAV、TBEV、黄熱ウイルス、風疹ウ イルス、HCV、ムンプスウイルス、麻疹ウイルス、RSウイルス、インフルエ ンザウイルス、ラッサウイルス、フニンウイルス、レオウイルス3型、アデノウ イルス1〜47型、HSV1、HSV2、CMV、VZV、EBV、ロタウイル ス、およびワクシニアウイルスからなる群から選ばれるものである請求項3に記 載の方法。 5.該ウイルスがインフルエンザウイルスである請求項4に記載の方法。 6.インフルエンザウイルスが血球凝集素中の開裂部位を修飾するかまたは新 しい開裂部位を生じる様に変化している請求項5に記載の方法。 7.該細胞がVERO細胞、CV−1細胞、LLC−MK2細胞、MDCK細 胞、MDBK細胞、WI−38細胞、およびMRC−5細胞からなる群から選ば れるものである請求項1に記載の方法。 8.該細胞がVERO細胞である請求項7に記載の方法。 9.VERO細胞がバイオマスを形成するものである請求項7に記載の方法。 10.さらに、(d)工程(c)の培養の部分を取り出し、 (e)工程(d)の該部分を該ウイルスの活性化を増強する少なくとも1つの物 質と接触させ、 (f)工程(e)の該部分に、該物質のあらゆる細胞毒性作用を阻害するかまた は減弱させる少なくとも1つの化合物を加え、 (g)工程(f)の該部分を該培養に戻す工程を含む請求項1に記載の方法。 11.該ウイルスの活性化を増強する該物質がプロテアーゼである請求項10 に記載の方法。 12.該ウイルスがインフルエンザであり、該プロテアーゼがインフルエンザ 血球凝集素を開裂させるものである請求項11に記載の方法。 13.該プロテアーゼが原核細胞供給源由来である請求項12に記載の方法。 14.該プロテアーゼがプロナーゼ、サーモリシン、またはサブチリシンAか らなる群から選ばれるものである請求項13に記載の方法。 15.該活性化を増強する該物質が容器中にあるかまたは担体上に固定されて いるものである請求項10に記載の方法。 16.該物質のあらゆる細胞毒性作用を阻害するかまたは減弱させる該化合物 がダイズトリプシンインヒビター、卵トリプシンインヒビター、およびアプロチ ニンからなる群から選ばれるものである請求項10に記載の方法。 17.該物質の細胞毒性作用を阻害するかまたは減弱させる化合物が容器中に あるかまたは担体上に固定化されているものである請求項16に記載の方法。 18.工程(a)−(d)が第1容器中で行われ、工程(e)−(f)が第2 容器中で行われるものである請求項10に記載の方法。 19.第1容器および第2容器が、工程(a)−(g)を環状で行い得るよう にループに接続されているものである請求項18に記載の方法。 20.工程(a)−(d)が第1容器中で行われ、工程(e)が第2容器中で行 われ、工程(f)が第3容器中で行われるものである請求項10に記載の方法。 21.第1容器、、第2容器、および第3容器が工程(a)−(g)を環状で行 い得るようにループに接続されているものである請求項20に記載の方法。、 22.工程(a)−(g)がバッチで行われるものである請求項21に記載の 方法。 23.さらに、(h)該培養の増殖、感染、および活性化レベルをモニターし 、 (i)増殖、感染、および活性化レベルを最大にするように該培養の条件を変え る工程を含む請求項10に記載の方法。 24.さらに(j)該培養から該ウイルスを回収する工程を含む請求項23に 記載の方法。 25.さらに(k)該回収されたウイルスを用いてワクチンを製造する工程を含 む請求項24に記載の方法。 26.該ウイルスがオルソミクソウイルス科、パラミクソウイルス科、および レオウイルス科からなる群から選ばれるものである請求項1〜25のいずれかに 記載の方法。 27.請求項1〜26のいずれかに記載の方法によって生産されるインフルエ ンザウイルス。 28.ヒト供給源、またはブタ、ウシ、ヒツジ、およびニワトリ(卵)のよう な動物供給源由来の蛋白、または病原性物質である蛋白のような培養液由来の夾 雑蛋白を含まない培養ウイルス。 29.請求項1に記載の方法によって得られる請求項28に記載のウイルス。 30.ヒト供給源、またはブタ、ウシ、ヒツジ、およびニワトリ(卵)のよう な動物供給源由来の蛋白、または病原性物質である蛋白のような培養液由来の夾 雑蛋白を含まないウイルス抗原。 31.TBEV、HAV、HSV、またはインフルエンザウイルス由来の請求 項28〜30のいずれかに記載のウイルスまたはウイルス抗原。 32.請求項28〜31のいずれかに記載のウイルスまたはウイルス抗原を含 むワクチン。 33.ウイルスまたはウイルス抗原および医薬的に許容される担体を含む請求 項32に記載のワクチン。 34.ウイルスが弱毒ウイルスである請求項32または33に記載のワクチン 。 35.該ウイルスが不活化されているものである請求項32または33に記載 のワクチン。 36.ウイルス感染に対して哺乳動物を免疫するためのワクチンを製造するた めの請求項28〜31に記載のウイルスまたはウイルス抗原の使用。 37.インフルエンザウイルス感染に対して哺乳動物を免疫するためのワクチ ンを製造するための請求項28〜31に記載のインフルエンザウイルスまたはウ イルス抗原の使用。 38.TBEウイルス感染に対して哺乳動物を免疫するためのワクチンを製造 するための請求項28〜31に記載のTBEウイルス/ウイルス抗原の使用。 39.ヘルペスウイルス感染に対して哺乳動物を免疫するためのワクチンを製 造するための請求項28〜31に記載のHSV/HSV抗原の使用。 40.A型肝炎ウイルス感染に対して哺乳動物を免疫するためのワクチンを製 造するための請求項28〜31に記載のA型肝炎ウイルス/ウイルス抗原の使用 。 41.(a)無蛋白培地のみで培養した脊椎動物細胞培養を得、 (b)該細胞培養を、組換え蛋白を発現するウイルスベクターに感染させ、 (c)該ウイルスベクターに感染させた該細胞培養を培養して該ウイルスを増殖 させ、 (d)該組換え蛋白を回収する工程を含む組換え蛋白の製造方法。 42.該ウイルスベクターがワクシニアウイルスである請求項41に記載の方 法。 43.該組換え蛋白がウイルス蛋白、細菌蛋白、および血液因子からなる群か ら選ばれるものである請求項41に記載の方法。 44.請求項41に記載の方法によって得ることができる組換え蛋白。 45.無蛋白条件下のみで培養した脊椎動物細胞を含む細胞バイオマスであっ て、ウイルスを該細胞で継代することなしにウイルスを増殖させ続けるものであ る細胞バイオマス。 46.該細胞が無蛋白条件下で連続的に継代されるものである請求項45に記 載の細胞バイオマス。 47.無蛋白培地中の担体上で該細胞を増殖させて得られるものである請求項 45および46に記載の細胞バイオマス。 48.該バイオマスが脊椎動物細胞、好ましくはVERO細胞を含むものであ る請求項45〜47に記載の細胞バイオマス。 49.(a)細胞が担体上で増殖し、該担体に吸着されたバイオマスを形成す るように担体および無蛋白培地を含む容器中で無蛋白条件下のみで細胞を増殖さ せ、 (b)該バイオマスおよび該担体を、該担体から該バイオマスを引き離す物質と 接触させる工程を含む細胞バイオマスの製造法。 50.該物質がプロテアーゼ、好ましくはサーモリシン、サブチリシンA、ま たはプロナーゼのような原核生物由来のプロテアーゼである請求項49に記載の 方法。 51.(a)無蛋白培地中のみで脊椎動物細胞培養を増殖させ、 (b)該培養にオルソミクソウイルスを感染させ、 (c)オルソミクソウイルスを感染させた該細胞培養をインキュベーションし、 (d)脊椎動物細胞中で所望の表現型を示すオルソミクソウイルス株を選択し、 (e)工程(d)から該ドナーオルソミクソウイルスを分離する工程を含む再集 合体ウイルスを製造するためのドナーオルソミクソウイルスの製造法。 52.所望の表現型が高収量表現型または弱毒有毒表現型である請求項51に 記載のウイルス製造法。 53.該ウイルスが弱毒インフルエンザウイルス、低温順化インフルエンザウ イルス、温度感受性インフルエンザウイルス、再結合体インフルエンザウイルス 、高収量ドナーインフルエンザウイルス、感染哺乳動物の咽頭スワブから分離さ れた野生型インフルエンザウイルス、およびニワトリ有胚卵またはインフルエン ザウイルス亜株に順化した細胞培養で継代されたウイルスからなる群から選ばれ るものである請求項51に記載のウイルス製造法。 54.該細胞がVERO細胞、CV−1細胞、LLC−MK2細胞、MDCK 細胞、およびMDBK細胞からなる群から選ばれるものである請求項51に記載 の方法。 55.該ウイルスがA/Orth/17/95(H1N1)であり、VERO細胞中で高収量表現 型を有するものである請求項51に記載の方法によって得られる高収量ドナーイ ンフルエンザウイルス。 56.(a)無蛋白培地中の脊椎動物細胞培養を、高収量表現型を有する第1 オルソミクソウイルスおよび少なくとも1つの抗原決定基を有する第2オルソミ クソウイルスに共感染させ、 (b)工程(a)の脊椎動物細胞培養をインキュベーションして該ウイルスおよ び該ウイルスの再結合体を増殖させ、 (c)該共感染培養から、該第1オルソミクソウイルスの高収量表現型および該 第2オルソミクソウイルスの少なくとも1つの抗原決定基を含む再結合体ウイル スを選択する工程を含む再結合体オルソミクソウイルスの製造法。 57.該オルソミクソウイルス系のウイルスがインフルエンザウイルスである 請求項56に記載の方法。 58.工程(c)が、該第1ウイルスの抗原決定基と結合するが該第2ウイルス の抗原決定基には結合しない抗体を使用するものである請求項56に記載の方法 。 59.該第2オルソミクソウイルスがワクチン製造用に選定されたものである 請求項56に記載の方法。 60.該脊椎動物細胞培養がVERO細胞のバイオマスである請求項56に記 載の方法。 61.(a)無蛋白培地中の脊椎動物細胞培養を、弱毒有毒表現型を有する第 1オルソミクソウイルスおよび少なくとも1つの抗原決定基を有する第2オルソミ クソウイルスに共感染させ、 (b)工程(a)の脊椎動物細胞培養をインキュベーションして該ウイルスおよ び該ウイルスの再結合体を増殖させ、 (c)該共感染培養から、該第1オルソミクソウイルスの弱毒有毒表現型および 該第2オルソミクソウイルスの少なくとも1つの抗原決定基を含む再結合体ウイ ルスを選択する工程を含む再結合体オルソミクソウイルスの製造法。 62.該オルソミクソウイルス系のウイルスがインフルエンザウイルスである 請求項61に記載の方法。 63.工程(c)が、該第1ウイルスの抗原決定基と結合するが該第2ウイルス の抗原決定基には結合しない抗体を使用するものである請求項61に記載の方法 。 64.該第2オルソミクソウイルスがワクチン製造用に選定されたものである 請求項61に記載の方法。 65.該脊椎動物細胞培養がVERO細胞のバイオマスである請求項61に記 載の方法。 66.抗体がドナーウイルスの抗原決定基と結合するがワクチン製造用に選定 されたウイルスの抗原決定基には結合しないものであるウイルス製造用の再結合 体ウイルスを選ぶための抗体。 67.抗体が該ドナー抗体の該表面糖蛋白と結合するものである請求項66に 記載の抗体。 68.該糖蛋白が血球凝集素およびノイラミニダーゼからなる群から選ばれる ものである請求項67に記載の抗体。 69.(a)無蛋白培地中のみで培養した脊椎動物細胞培養を得、 (b)該培養に、該細胞中の開裂酵素に対するウイルスの感受性を増加させるよ うに血球凝集素中の開裂部位が修飾されたウイルスを感染させ、 (c)該ウイルスを感染させた該細胞培養をインキュベーションして該ウイルス を増殖させ、ウイルス含有培地を調製する工程を含むウイルスの活性化に関与す る蛋白を発現させるウイルスの感染性を増加させる方法。 70.さらに、(d)工程(c)の培養の部分を取り出し、 (e)工程(d)の該部分を、該ウイルスの活性化を増強する少なくとも1つの 物質と接触させ、 (f)工程(e)の該部分に、該物質のあらゆる細胞毒性作用を阻害または減弱 させる少なくとも1つの化合物を加え、 (g)該培養に工程(f)の該部分を戻す工程を含む請求項69に記載の方法。 71.(A)第1容器に培地中の細胞を入れ、 (B)該細胞の部分を第2容器に移し、 (C)所望の生成物の生産を最適化するための少なくとも1つの外因性物質を加 えることにより該第2容器中の該細胞の該部分を活性化し、 (D)工程(C)の該細胞の該部分を第3容器に移し、 (E)該第3容器中の該細胞の該部分に、該外因性物質のあらゆる細胞毒性作用 を減弱させる化合物を加え、 (F)該細胞の該部分を該第1容器にもどす(ここで、該第1、第2、および第3容 器は環状ループ系に接続されている)工程を含む1またはそれ以上の培養細胞生 成物の生産を最適化する方法。
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33876194A | 1994-11-10 | 1994-11-10 | |
US08/338,761 | 1994-11-10 | ||
US48722295A | 1995-06-07 | 1995-06-07 | |
US487,222 | 1995-06-07 | ||
US08/483.522 | 1995-06-07 | ||
US08/487,222 | 1995-06-07 | ||
US338,761 | 1995-06-07 | ||
US08/487,046 | 1995-06-07 | ||
US483.522 | 1995-06-07 | ||
US08/487,046 US5753489A (en) | 1994-11-10 | 1995-06-07 | Method for producing viruses and vaccines in serum-free culture |
US08/483,522 US5756341A (en) | 1994-11-10 | 1995-06-07 | Method for controlling the infectivity of viruses |
US487,046 | 1995-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10503093A true JPH10503093A (ja) | 1998-03-24 |
JP3158157B2 JP3158157B2 (ja) | 2001-04-23 |
Family
ID=27502591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51572696A Expired - Fee Related JP3158157B2 (ja) | 1994-11-10 | 1995-11-10 | 無蛋白培養における生物製剤の製造法 |
Country Status (10)
Country | Link |
---|---|
EP (3) | EP1213030B1 (ja) |
JP (1) | JP3158157B2 (ja) |
AT (2) | ATE542891T1 (ja) |
CA (2) | CA2205015C (ja) |
DE (1) | DE69535940D1 (ja) |
DK (2) | DK1213030T3 (ja) |
ES (2) | ES2378409T3 (ja) |
FI (1) | FI121117B (ja) |
HK (1) | HK1002285A1 (ja) |
WO (1) | WO1996015231A2 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005511087A (ja) * | 2001-12-10 | 2005-04-28 | バクスター・ヘルスケヤー・ソシエテ・アノニム | プロナーゼからのトリプシンの単離および精製の方法ならびにそれらの使用 |
JP2005511078A (ja) * | 2001-12-10 | 2005-04-28 | バクスター・ヘルスケヤー・ソシエテ・アノニム | A型肝炎ウイルスの大規模生成の方法 |
JP2005511077A (ja) * | 2001-12-10 | 2005-04-28 | バクスター・ヘルスケヤー・ソシエテ・アノニム | 精製a型肝炎ウイルス粒子およびワクチン調製物の生成方法 |
JP2008526239A (ja) * | 2005-01-14 | 2008-07-24 | アレキサンダー,ロバート | ウイルス回復培地、その使用、及びウイルス回復培地を具えるウイルス診断キット |
JP2012034712A (ja) * | 2002-07-09 | 2012-02-23 | Baxter Internatl Inc | 細胞を培養するための動物性タンパク質非含有培地 |
JP2013531481A (ja) * | 2010-05-21 | 2013-08-08 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
WO2018012498A1 (ja) * | 2016-07-15 | 2018-01-18 | 一般財団法人阪大微生物病研究会 | リアソータントインフルエンザウイルス作出方法 |
WO2019044636A1 (ja) * | 2017-08-28 | 2019-03-07 | 一般財団法人阪大微生物病研究会 | リアソータントインフルエンザウイルスの段階的作出方法 |
WO2020004425A1 (ja) * | 2018-06-27 | 2020-01-02 | 一般財団法人阪大微生物病研究会 | インフルエンザウイルスの培養方法 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
DE19655440B4 (de) * | 1996-04-01 | 2013-09-05 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur Herstellung eines Influenzaimpfstoffs |
AU4330597A (en) * | 1996-08-30 | 1998-03-19 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
US6110724A (en) * | 1996-10-18 | 2000-08-29 | The Research Foundation For Microbial Diseases Of Osaka University | Rotavirus antigen, vaccine and diagnostic agent for rotavirus infections, and a method for producing the antigen |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
AT408615B (de) * | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
AU780810B2 (en) * | 1999-08-05 | 2005-04-21 | Baxalta GmbH | Recombinant stable cell clone, its production and use thereof |
EP1211309A4 (en) * | 1999-08-20 | 2003-02-12 | METHOD AND DEVICE FOR PROPAGING HEPATITISVIRUS | |
DE60142506D1 (de) | 2000-03-03 | 2010-08-19 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
WO2004022729A1 (en) | 2002-09-05 | 2004-03-18 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
DE10144906B4 (de) * | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
US6951752B2 (en) | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
US7195905B2 (en) | 2001-12-10 | 2007-03-27 | Baxter Healthcare S.A. | Enveloped virus vaccine and method for production |
CU23097A1 (es) | 2002-10-23 | 2005-11-18 | Centro Inmunologia Molecular | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método |
GB0304799D0 (en) | 2003-03-03 | 2003-04-09 | Glaxosmithkline Biolog Sa | Novel method |
US8221969B2 (en) | 2004-04-19 | 2012-07-17 | Sanyo Chemical Industries, Ltd. | Method of producing virus |
DE602005024827D1 (de) | 2004-09-09 | 2010-12-30 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
EP2522717B1 (en) | 2006-01-04 | 2014-04-02 | Baxter International Inc | Oligopeptide-free cell culture media |
EP1982727A1 (en) * | 2007-04-17 | 2008-10-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for purification of viral proteins |
KR101190605B1 (ko) | 2007-06-15 | 2012-10-15 | 재단법인 목암생명공학연구소 | 활성형 재조합 혈액응고 9인자의 대량생산 방법 |
DK2373783T3 (da) | 2008-12-30 | 2018-01-29 | Baxalta GmbH | Fremgangsmåde til at forbedre cellevækst under anvendelse af alkyl-amin-n-oxid (aanox) |
WO2010079081A1 (en) * | 2009-01-07 | 2010-07-15 | Glaxosmithkline Biologicals S.A. | Methods for recovering a virus or a viral antigen produced by cell culture |
DK2396032T3 (en) | 2009-02-10 | 2016-12-19 | Seqirus Uk Ltd | Influenza vaccines with reduced amounts of squalene |
US20120058145A1 (en) * | 2009-05-08 | 2012-03-08 | Bruno Rene Andre | Method for producing virus from cell culture involving homogenization |
BR122021005965B1 (pt) | 2009-07-31 | 2022-01-25 | Baxalta Incorporated | Método para produzir uma composição de desintegrina e metaloproteinase com motivo trombospondina (adamts) |
AU2015258263B2 (en) * | 2010-05-21 | 2017-12-07 | Seqirus UK Limited | Influenza virus reassortment method |
TR201815211T4 (tr) | 2010-07-08 | 2018-11-21 | Baxalta GmbH | Hücre kültüründe rekombinant adamts13 üretmeye yönelik yöntem. |
CA2866465A1 (en) | 2012-03-06 | 2013-09-12 | Crucell Holland B.V. | Improved vaccination against influenza |
WO2014004103A1 (en) | 2012-06-29 | 2014-01-03 | Emd Millipore Corporation | Methods for inactivating viruses during a protein purification process |
EP2890779B1 (en) | 2012-08-31 | 2017-10-04 | The Governors of the University of Alberta | Methods for producing cells having a phenotype of primary human hepatocytes and compositions |
US10527551B2 (en) | 2013-12-30 | 2020-01-07 | Baxalta Incorporated | Method of predicting a performance characteristic of a plant or yeast hydrolysate and its use |
EP2966093A1 (en) | 2014-07-07 | 2016-01-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use |
KR101869010B1 (ko) | 2016-09-09 | 2018-06-20 | 주식회사 포스코 | 이물 제거장치 |
RU2738404C1 (ru) * | 2019-08-26 | 2020-12-11 | Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" | Способ инактивации культурального ротавируса человека |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE445466B (sv) * | 1977-12-01 | 1986-06-23 | Wellcome Found | Sett att foroka rotavirus in vitro |
CA1122527A (en) * | 1979-05-15 | 1982-04-27 | Karen K. Brown | Influenza vaccine production in liquid cell culture |
US4500513A (en) | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
GB8300467D0 (en) * | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
US5136019A (en) | 1989-05-24 | 1992-08-04 | Sri International | Synthetic peptides for diagnosis and prevention of influenza virus infection and their use |
AT393356B (de) * | 1989-12-22 | 1991-10-10 | Immuno Ag | Verfahren zur herstellung von fsme-virus-antigen |
AT393277B (de) | 1990-01-04 | 1991-09-25 | Immuno Ag | Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen |
JPH04228066A (ja) * | 1990-10-23 | 1992-08-18 | Rikagaku Kenkyusho | 外来遺伝子発現用培養細胞 |
EP0531562A1 (de) | 1991-09-11 | 1993-03-17 | Doerr, Hans-Wilhelm, Prof. Dr. med. | Kultivierung von Säugetierzellen |
-
1995
- 1995-11-10 WO PCT/EP1995/004439 patent/WO1996015231A2/en active Application Filing
- 1995-11-10 CA CA 2205015 patent/CA2205015C/en not_active Expired - Fee Related
- 1995-11-10 AT AT95937888T patent/ATE542891T1/de active
- 1995-11-10 ES ES95937888T patent/ES2378409T3/es not_active Expired - Lifetime
- 1995-11-10 JP JP51572696A patent/JP3158157B2/ja not_active Expired - Fee Related
- 1995-11-10 DK DK01130212T patent/DK1213030T3/da active
- 1995-11-10 EP EP20010130212 patent/EP1213030B1/en not_active Expired - Lifetime
- 1995-11-10 DK DK95937888T patent/DK0791055T3/da active
- 1995-11-10 EP EP20100179339 patent/EP2290053A1/en not_active Ceased
- 1995-11-10 EP EP95937888A patent/EP0791055B1/en not_active Expired - Lifetime
- 1995-11-10 ES ES01130212T patent/ES2323490T3/es not_active Expired - Lifetime
- 1995-11-10 DE DE69535940T patent/DE69535940D1/de not_active Expired - Lifetime
- 1995-11-10 CA CA 2415990 patent/CA2415990C/en not_active Expired - Fee Related
- 1995-11-10 AT AT01130212T patent/ATE429246T1/de active
-
1997
- 1997-05-09 FI FI971998A patent/FI121117B/fi not_active IP Right Cessation
-
1998
- 1998-02-19 HK HK98101284A patent/HK1002285A1/xx not_active IP Right Cessation
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005511078A (ja) * | 2001-12-10 | 2005-04-28 | バクスター・ヘルスケヤー・ソシエテ・アノニム | A型肝炎ウイルスの大規模生成の方法 |
JP2005511077A (ja) * | 2001-12-10 | 2005-04-28 | バクスター・ヘルスケヤー・ソシエテ・アノニム | 精製a型肝炎ウイルス粒子およびワクチン調製物の生成方法 |
JP2005511087A (ja) * | 2001-12-10 | 2005-04-28 | バクスター・ヘルスケヤー・ソシエテ・アノニム | プロナーゼからのトリプシンの単離および精製の方法ならびにそれらの使用 |
US9163211B2 (en) | 2002-07-09 | 2015-10-20 | Baxter International Inc. | Animal protein free media for cultivation of cells |
JP2012034712A (ja) * | 2002-07-09 | 2012-02-23 | Baxter Internatl Inc | 細胞を培養するための動物性タンパク質非含有培地 |
JP2008526239A (ja) * | 2005-01-14 | 2008-07-24 | アレキサンダー,ロバート | ウイルス回復培地、その使用、及びウイルス回復培地を具えるウイルス診断キット |
JP2013531481A (ja) * | 2010-05-21 | 2013-08-08 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
JP2016063831A (ja) * | 2010-05-21 | 2016-04-28 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
WO2018012498A1 (ja) * | 2016-07-15 | 2018-01-18 | 一般財団法人阪大微生物病研究会 | リアソータントインフルエンザウイルス作出方法 |
JP6335399B1 (ja) * | 2016-07-15 | 2018-05-30 | 一般財団法人阪大微生物病研究会 | リアソータントインフルエンザウイルス作出方法 |
US11633469B2 (en) | 2016-07-15 | 2023-04-25 | The Research Foundation For Microbial Diseases Of Osaka University | Reassortant influenza virus production method |
WO2019044636A1 (ja) * | 2017-08-28 | 2019-03-07 | 一般財団法人阪大微生物病研究会 | リアソータントインフルエンザウイルスの段階的作出方法 |
WO2020004425A1 (ja) * | 2018-06-27 | 2020-01-02 | 一般財団法人阪大微生物病研究会 | インフルエンザウイルスの培養方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2415990A1 (en) | 1996-05-23 |
ES2378409T3 (es) | 2012-04-12 |
JP3158157B2 (ja) | 2001-04-23 |
EP0791055B1 (en) | 2012-01-25 |
FI971998A (fi) | 1997-05-09 |
DK0791055T3 (da) | 2012-04-16 |
ATE542891T1 (de) | 2012-02-15 |
DK1213030T3 (da) | 2009-07-20 |
CA2205015A1 (en) | 1996-05-23 |
DE69535940D1 (de) | 2009-06-04 |
EP1213030A1 (en) | 2002-06-12 |
HK1002285A1 (en) | 1998-08-14 |
EP0791055A1 (en) | 1997-08-27 |
CA2205015C (en) | 2003-04-08 |
CA2415990C (en) | 2009-07-07 |
ATE429246T1 (de) | 2009-05-15 |
EP1213030B1 (en) | 2009-04-22 |
EP2290053A1 (en) | 2011-03-02 |
ES2323490T3 (es) | 2009-07-17 |
FI971998A0 (fi) | 1997-05-09 |
WO1996015231A2 (en) | 1996-05-23 |
FI121117B (fi) | 2010-07-15 |
WO1996015231A3 (en) | 1996-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3158157B2 (ja) | 無蛋白培養における生物製剤の製造法 | |
US6146873A (en) | Production of orthomyxoviruses in monkey kidney cells using protein-free media | |
US5753489A (en) | Method for producing viruses and vaccines in serum-free culture | |
US7494659B2 (en) | Live attenuated influenza vaccine | |
JP5264843B2 (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
EP0904351B1 (en) | Animal cells and processes for the replication of influenza viruses | |
JP5686741B2 (ja) | インフルエンザワクチンの生成 | |
AU2002223560A1 (en) | Live influenza vaccine and method of manufacture | |
WO2005024039A2 (en) | Improved method for generating influenza viruses and vaccines | |
US5756341A (en) | Method for controlling the infectivity of viruses | |
JP5762969B2 (ja) | pH安定性のエンベロープ付きウィルスの生産方法 | |
US5698433A (en) | Method for producing influenza virus and vaccine | |
Merten et al. | Virus production under suspension conditions | |
RU2460796C2 (ru) | Рекомбинантный вирусный вектор и система экспрессии в клетках растения гибридного белка, включающего внеклеточный домен белка м2 вируса гриппа, присоединенный к ядерному антигену вируса гепатита в |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090216 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100216 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100216 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110216 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120216 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130216 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130216 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140216 Year of fee payment: 13 |
|
LAPS | Cancellation because of no payment of annual fees |